Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1813527-81-9

Post Buying Request

1813527-81-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1813527-81-9 Usage

General Description

CCG215022 is a synthetic compound that acts as a potent and selective inhibitor of the enzyme histone lysine methyltransferase, G9a. It has been shown to inhibit G9a in vitro, leading to a decrease in the levels of di- and trimethylated histone H3 lysine 9 (H3K9me2/3) and subsequent attenuation of G9a-mediated gene silencing. Additionally, CCG215022 has demonstrated promising anti-cancer properties in preclinical studies, specifically in the context of leukemia, breast cancer, and prostate cancer. Its ability to inhibit G9a and restore expression of tumor suppressor genes makes CCG215022 a potential therapeutic agent for the treatment of various malignancies. Further research and development of CCG215022 may lead to its application in clinical settings for the treatment of cancer.

Check Digit Verification of cas no

The CAS Registry Mumber 1813527-81-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,1,3,5,2 and 7 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1813527-81:
(9*1)+(8*8)+(7*1)+(6*3)+(5*5)+(4*2)+(3*7)+(2*8)+(1*1)=169
169 % 10 = 9
So 1813527-81-9 is a valid CAS Registry Number.

1813527-81-9Downstream Products

1813527-81-9Relevant articles and documents

Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors

Waldschmidt, Helen V.,Homan, Kristoff T.,Cruz-Rodríguez, Osvaldo,Cato, Marilyn C.,Waninger-Saroni, Jessica,Larimore, Kelly M.,Cannavo, Alessandro,Song, Jianliang,Cheung, Joseph Y.,Kirchhoff, Paul D.,Koch, Walter J.,Tesmer, John J. G.,Larsen, Scott D.

, p. 3793 - 3807 (2016/05/24)

G protein-coupled receptors (GPCRs) are central to many physiological processes. Regulation of this superfamily of receptors is controlled by GPCR kinases (GRKs), some of which have been implicated in heart failure. GSK180736A, developed as a Rho-associated coiled-coil kinase 1 (ROCK1) inhibitor, was identified as an inhibitor of GRK2 and co-crystallized in the active site. Guided by its binding pose overlaid with the binding pose of a known potent GRK2 inhibitor, Takeda103A, a library of hybrid inhibitors was developed. This campaign produced several compounds possessing high potency and selectivity for GRK2 over other GRK subfamilies, PKA, and ROCK1. The most selective compound, 12n (CCG-224406), had an IC50 for GRK2 of 130 nM, >700-fold selectivity over other GRK subfamilies, and no detectable inhibition of ROCK1. Four of the new inhibitors were crystallized with GRK2 to give molecular insights into the binding and kinase selectivity of this class of inhibitors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1813527-81-9